Testosterone replacement therapy and bladder cancer.

Area of Science:

• Oncology
• Endocrinology

Background:

• Muscle-invasive bladder cancer treatment involves neoadjuvant chemotherapy and radical cystectomy, which have significant morbidity.
• Current treatments can lead to skeletal muscle atrophy, reduced body mass, and high blood loss requiring transfusion.
• The role of androgens in bladder cancer is not well understood, with conflicting data on anti-androgen therapies.

Purpose of the Study:

• To present a rationale for using preoperative testosterone in muscle-invasive bladder cancer patients.
• To explore the potential benefits of testosterone in mitigating treatment-related side effects.
• To lay the groundwork for a future clinical trial investigating preoperative testosterone in this patient population.

Main Methods:

• This is a review article, not an experimental study.
• The authors present a theoretical basis and supporting evidence for the proposed intervention.
• The review synthesizes existing knowledge on androgens, cancer, and surgical recovery.

Main Results:

• Preoperative testosterone is hypothesized to prevent skeletal muscle atrophy associated with neoadjuvant chemotherapy.
• Testosterone may help maintain normal hematocrit levels, potentially reducing the need for blood transfusions during radical cystectomy.
• The intervention is considered inexpensive, feasible, and associated with minimal adverse effects in other patient groups.

Conclusions:

• Preoperative testosterone presents a promising, low-cost strategy to improve outcomes for muscle-invasive bladder cancer patients.
• Further clinical trials are needed to validate the efficacy and safety of preoperative testosterone in this specific cancer type.
• This approach could enhance postoperative recovery and reduce treatment-related complications.